These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2193498)

  • 21. Procainamide induced sustained monomorphic ventricular tachycardia in a patient with benign premature ventricular complexes.
    Bhandari AK; Au PK; Rahimtoola SH
    Can J Cardiol; 1986; 2(1):6-9. PubMed ID: 2420424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic effects of intravenous procainamide during ventricular tachycardia.
    Sharma AD; Purves P; Yee R; Klein G; Jablonsky G; Kostuk WJ
    Am Heart J; 1990 May; 119(5):1034-41. PubMed ID: 2330861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators.
    Kerin NZ; Meengs WL; Timmis GC; Salerno D; Haber HE; Singer RM
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):169-75. PubMed ID: 9140693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia.
    Somberg JC; Butler B; Flowers D; Keefe D; Torres V; Miura D
    Am J Cardiol; 1984 Aug; 54(4):43B-48B. PubMed ID: 6465046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
    Nademanee K; Singh BN
    Am J Cardiol; 1990 Jan; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia.
    Myerburg RJ; Kessler KM; Kiem I; Pefkaros KC; Conde CA; Cooper D; Castellanos A
    Circulation; 1981 Aug; 64(2):280-90. PubMed ID: 7249296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison.
    Marill KA; deSouza IS; Nishijima DK; Senecal EL; Setnik GS; Stair TO; Ruskin JN; Ellinor PT
    Acad Emerg Med; 2010 Mar; 17(3):297-306. PubMed ID: 20370763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery.
    Gold MR; O'Gara PT; Buckley MJ; DeSanctis RW
    Am J Cardiol; 1996 Nov; 78(9):975-9. PubMed ID: 8916473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia.
    Rials SJ; Britchkow D; Marinchak RA; Kowey PR
    Clin Cardiol; 2000 Mar; 23(3):171-4. PubMed ID: 10761804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia.
    Gorgels AP; van den Dool A; Hofs A; Mulleneers R; Smeets JL; Vos MA; Wellens HJ
    Am J Cardiol; 1996 Jul; 78(1):43-6. PubMed ID: 8712116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio.
    Pratt CM; Eaton T; Francis M; Woolbert S; Mahmarian J; Roberts R; Young JB
    Am Heart J; 1989 Sep; 118(3):433-40. PubMed ID: 2476016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
    J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of procainamide on induced ventricular tachycardia.
    Engel TR; del Gonzalez A; Meister SG; Franki WS
    Clin Pharmacol Ther; 1978 Sep; 24(3):274-82. PubMed ID: 688720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics.
    Holland DR; Lacefield WB; Gonzales CR; Johnston SR; Turk JA
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):454-61. PubMed ID: 2476626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity.
    Mahmarian JJ; Smart FW; Moyé LA; Young JB; Francis MJ; Kingry CL; Verani MS; Pratt CM
    Am J Cardiol; 1994 Oct; 74(7):681-6. PubMed ID: 7524296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans.
    Kidwell GA; Greenspon AJ; Greenberg RM; Volosin KJ
    Circulation; 1993 Jan; 87(1):118-25. PubMed ID: 8418998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic action of bethanidine.
    Somberg JC; Butler B; Torres V; Flowers D; Tepper D; Wynn J; Keren G; Miura DS
    Am J Cardiol; 1984 Aug; 54(3):343-6. PubMed ID: 6465015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiologic assessment of antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy.
    Rae AP; Spielman SR; Kutalek SP; Kay HR; Horowitz LN
    Am J Cardiol; 1987 Feb; 59(4):291-5. PubMed ID: 3544793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease.
    Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC
    Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.